Psychedelics


Bionomics Announces Plans to Conduct U.S. Initial Public Offering

August 2nd, 2021 - Ryan Allway

ADELAIDE, Australia, Aug. 2, 2021 /PRNewswire/ — Bionomics Limited (ASX: BNO,OTCQB: BNOEF), (Bionomics) a global, clinical stage biopharmaceutical company, is pleased to announce that it plans to conduct a registered initial public offering of American Depositary Shares (ADSs) in the United States and a concurrent listing of ADSs on Nasdaq. The number of ADSs and price […]

Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

July 30th, 2021 - Ryan Allway

Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols   Vancouver, British Columbia–(Newsfile Corp. – July 30, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a […]

New CBD Trials Point the Way for Enveric, MagicMed

July 30th, 2021 - Ryan Allway

  As the cannabis industry strives to gain widespread acceptance in the mainstream, scientific studies into the potential benefits of the plant and its active ingredients play a key role in reaching that goal. There are currently very few approved pharmaceutical drug applications for cannabinoids, but that could change. After decades of effective prohibition there […]

Regulatory Approvals Place Filament Health at the Forefront of Natural Psychedelic Research and Manufacturing

July 29th, 2021 - Ryan Allway

Health Canada Dealer’s License to allow the possession, production, and delivery of all controlled natural psychedelic substances   VANCOUVER, BC , July 29, 2021 /CNW/ – Filament Health Corp. (NEO: FH) (“Filament” or the “Company”), a global leader in natural psychedelic drug development, has been granted an amendment to its existing Health Canada Dealer’s License, amplifying the Company’s position at the […]

Levitee Labs Acquires Five Addiction Clinics in Alberta

July 29th, 2021 - Ryan Allway

Levitee acquires the majority of the operating assets of ACT Medical Centres Inc. Five acquired addiction clinics have conducted 35,000+ patient visits over last 12 months Clinics will be integrated with Levitee’s growing portfolio of healthcare assets   VANCOUVER, BC, July 29, 2021 /CNW/ – Levitee Labs Inc. (CSE: LVT) (the “Company” or “Levitee”), an integrative wellness company with a diversified […]

Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics

July 29th, 2021 - Ryan Allway

VANCOUVER, BC, July 29, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announced it has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of psilocybin and […]

Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave

July 29th, 2021 - Ryan Allway

HPPD is a psychiatric disorder characterized by the persisting presence of sensory disturbances, most commonly visual, that resemble those produced by the use of hallucinogenic substances. Ehave believes psychedelics are extremely safe, especially under medical supervision, but believes understanding HPPD will lead to a better understanding of these molecules as a whole MIAMI, July 29, 2021 (GLOBE […]

Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5

July 28th, 2021 - Ryan Allway

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for the listing of its common shares on the NYSE American LLC stock exchange (“NYSE American”). The Company expects its common shares will open for trading on the NYSE American on or […]

Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw

July 28th, 2021 - Ryan Allway

Vancouver, British Columbia–(Newsfile Corp. – July 28, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. Andrew (Andy) Greenshaw, Professor of Psychiatry and Neuroscience and Associate Chair (Research) for Psychiatry […]

Ketamine One Advances Research Capabilities via Controlled Substance Dealers Licence Application

July 28th, 2021 - Ryan Allway

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health July 28, 2021 07:00 ET | Source: KetamineOne Capital Limite VANCOUVER, British Columbia, July 28, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) […]

Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP

July 27th, 2021 - Ryan Allway

TORONTO, July 27, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (TSX: FTRP; FTRP.WT; OTCQX: FTRPF) (“Field Trip” or the “Company”), a global leader in the development and delivery of psychedelic therapies, announced today that it has received final approval from The NASDAQ Stock Market LLC (“NASDAQ”) to list its common shares on the NASDAQ […]

MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

July 27th, 2021 - Ryan Allway

MINDCURE’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.   VANCOUVER, BC, July 27, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, is pleased to […]

Medxtractor Corp. (“MedX” or the “Corporation”) (CSE: MXT, OTC:MXTTF) announces a Business Refocus

July 27th, 2021 - Ryan Allway

Calgary, Alberta –TheNewswire – July 27, 2021 – Medxtractor (“MedX” or the “Corporation”) (CSE:MXT), (CNSX:MXT.CN),(OTC:MXTTF) reports its plan to refocus to proprietary health-related databases, machine-learning analysis and associated applications. The planned changes are generally as follows: Continuing development of the proprietary health-related Reference Database (“RD”) and machine-learning training environments. The RD currently holds more than 700 reference records which consist […]

Silo Pharma Awarded Notice of Allowance from United States Patent and Trademark Office for Homing Peptide Patent

July 27th, 2021 - Ryan Allway

Central Nervous System Homing Peptide under development to deliver Psychedelics including Psilocybin Englewood Cliffs NJ, July 27, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB:SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announcedthat the United States Patent Office has issued a notice of allowance for a patent application related to […]

Psyched Wellness Enters into a Service Agreement with CannaLabs to Begin Stability Tests on AME-1

July 26th, 2021 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – July 26, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched“) a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce the Company has entered into a service agreement with CannaLabs, a Canadian, London-based laboratory services company, […]

Diamond Therapeutics Hires Industry Veteran David Brown, PhD, to Further Advance Formulation of Psilocybin

July 26th, 2021 - Ryan Allway

  TORONTO, July 26, 2021 /CNW/ – Diamond Therapeutics Inc. (“Diamond”), a drug development company focused on low-dose psychedelic therapies for use in the treatment of mental health, today announced the appointment of David Brown, PhD, as vice president, pharmaceutical development.   Brown has an impressive track record of experience, having held senior positions at […]

UK Psychedelics Co. Awakn Life Sciences Begins Listing On OTC Markets

July 26th, 2021 - Ryan Allway

Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF), a biotech company with clinical operations in the psychedelics space looking at the UK mental health markets, began trading on Monday in the U.S. OTC markets under the symbol “AWKNF.”   The new OTC listing will allow Awakn to reach a wider variety of investors. The company went […]

BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety

July 24th, 2021 - Ryan Allway

VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on developing compounds to treat neurological conditions, is pleased to announce funding of its joint application with Dr. Argel Aguilar-Valles at Carleton University (“Carleton”) Department of Neuroscience by the Accelerate program at Mitacs […]

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

July 24th, 2021 - Ryan Allway

DENVER, July 21, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that the Company has filed a new patent for MDMA-like compounds further expanding its […]

Psyched Wellness Successfully Completes Its Largest Extraction and Shipment of AME-1 to Asia

July 24th, 2021 - Ryan Allway

Toronto, Ontario–(Newsfile Corp. – July 22, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the company has completed its largest extraction of AME-1 to date, and has successfully shipped […]

Silo Pharma Takes Next Step in Bringing Homing Peptide Tech to $30+ Billion RA Market

July 23rd, 2021 - Ryan Allway

Rheumatoid arthritis, or RA, is an autoimmune and inflammatory disease that causes painful swelling in joints in the hands, wrists, and knees. While medications can slow the disease and prevent joint deformity, there is no cure for the condition, and many millions still suffer from it. Silo Pharma Inc. (OTCQB: SILO) is a development-stage biopharmaceutical […]

Meet DELIC, the Premiere Psychedelic and Wellness Edutainment Event and Expo for Newcomers and Veteran Psychonauts, Announces Initial Business Speaker Lineup

July 22nd, 2021 - Ryan Allway

Two-Day Experiential Experience to Help Scale the Business ofPsychedelic Wellness for the Growing Needs of the Mainstream VANCOUVER, BC, July 22, 2021 /PRNewswire/ – Delic Holdings Inc. (“DELIC” or the “Company“) (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform today announced its initial list of business speakers and panelists to take part in Meet DELIC, the world’s premiere […]

Levitee Labs Provides Company Update Following CSE Listing

July 22nd, 2021 - Ryan Allway

VANCOUVER, BC, July 22, 2021 /CNW/ – Levitee Labs Inc. (CSE: LVT) (the “Company” or “Levitee”) is pleased to provide insight into the Company’s achievements to date, current operations, and strategic initiatives. Levitee has ambitious plans to advance its business following its recent successful listing on the Canadian Securities Exchange. A review of the Company’s […]

Ketamine One’s IRP Clinic Using Innovative NeuroCatch Platform to Measure Brain Function in Injured Veterans The NeuroCatch Platform is a 6-Minute Brain Function Assessment System Licensed by Health Canada as a Class II Medical Device

July 22nd, 2021 - Ryan Allway

  VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) — KetamineOne Capital Limited (“Ketamine One” or the “Company”) (NEO: MEDI) (OTC: KONEF) (Frankfurt: MY0), a company focused on consolidating medical clinics and becoming a North American leader in mental health treatments, is pleased to highlight the continued success of the Health Canada-approved NeuroCatch Platform (“NeuroCatch”) in […]

Small Pharma Establishes Psychedelic-assisted Therapy Training Program

July 21st, 2021 - Ryan Allway

Training program established ahead of Phase II clinical trials Phase IIa due to start imminently and Phase IIb expected to commence in 2022     LONDON, July 21, 2021 /PRNewswire/ —  Small Pharma Inc. (TSXV: DMT) (the “Company” or “Small Pharma“), a neuropharmaceutical company focused on psychedelic-assisted N,N-dimethyltryptamine (“DMT“) therapies, has launched a training program to educate psychologists […]

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

July 21st, 2021 - Ryan Allway

Strengthens position to become a leader in the intradermal delivery of FDA prescription-based ketamine products Supports commercializing novel uses and delivery methods of psychedelics   TORONTO, July 21, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that it has filed a […]

Tryp Therapeutics Announces Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

July 21st, 2021 - Ryan Allway

The study is expected to be the world’s first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia   San Diego, California–(Newsfile Corp. – July 21, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (“Tryp”), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory […]

Cybin Announces Conditional Listing Approval from NYSE American

July 21st, 2021 - Ryan Allway

July 21, 2021 08:37 PM Eastern Daylight Time TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional listing approval from the NYSE American LLC stock exchange (the “NYSE American”).   Doug Drysdale, Cybin’s CEO, added, “Conditional listing approval on the NYSE […]

Cybin Announces Conditional Listing Approval from NYSE American

July 21st, 2021 - Ryan Allway

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional listing approval from the NYSE American LLC stock exchange (the “NYSE American”).   Doug Drysdale, Cybin’s CEO, added, “Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth […]

Silo Pharma To Appear On National Media Broadcast on Psychedelics

July 21st, 2021 - Ryan Allway

Englewood Cliffs, NJ , July 21, 2021 (GLOBE NEWSWIRE) —  Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, has announced that the company will be participating in a nationwide media tour on Thursday, July 22 from 8 a.m. – 11:30 a.m. EST. The company has […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading